Cellectis SA (NASDAQ:CLLS) — Market Cap & Net Worth
Market Cap & Net Worth: Cellectis SA (CLLS)
Cellectis SA (NASDAQ:CLLS) has a market capitalization of $106.17 Million ($106.17 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19069 globally and #4403 in its home market, demonstrating a -53.35% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cellectis SA's stock price $1.46 by its total outstanding shares 72718974 (72.72 Million). Also see CLLS total asset value for a full breakdown of the balance sheet.
Cellectis SA Market Cap History: 2015 to 2026
Cellectis SA's market capitalization history from 2015 to 2026. Data shows change from $2.26 Billion to $106.17 Million (-23.34% CAGR). Also see Cellectis SA operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Cellectis SA is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #544 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1845 of 3165 |
Weight: Cellectis SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cellectis SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cellectis SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check CLLS stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.82x
Cellectis SA's market cap is 4.82 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.23 Billion | $42.58 Million | -$63.92 Million | 28.94x | N/A |
| 2017 | $2.12 Billion | $25.19 Million | -$99.37 Million | 84.16x | N/A |
| 2018 | $1.21 Billion | $12.73 Million | -$78.69 Million | 95.10x | N/A |
| 2019 | $1.24 Billion | $15.19 Million | -$90.69 Million | 81.96x | N/A |
| 2020 | $1.97 Billion | $73.95 Million | -$72.57 Million | 26.61x | N/A |
| 2021 | $590.48 Million | $73.95 Million | -$86.28 Million | 7.98x | N/A |
| 2022 | $152.71 Million | $19.17 Million | -$98.69 Million | 7.97x | N/A |
| 2023 | $223.97 Million | $755.00K | -$101.06 Million | 296.65x | N/A |
| 2024 | $130.89 Million | $41.51 Million | -$36.76 Million | 3.15x | N/A |
| 2025 | $351.96 Million | $72.95 Million | -$67.59 Million | 4.82x | N/A |
Competitor Companies of CLLS by Market Capitalization
Companies near Cellectis SA in the global market cap rankings as of September 18, 2026. Review Cellectis SA tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cellectis SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Cellectis SA Historical Marketcap From 2015 to 2026
Between 2015 and today, Cellectis SA's market cap moved from $2.26 Billion to $ 106.17 Million, with a yearly change of -23.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $106.17 Million | -69.83% |
| 2025 | $351.96 Million | +168.89% |
| 2024 | $130.89 Million | -41.56% |
| 2023 | $223.97 Million | +46.67% |
| 2022 | $152.71 Million | -74.14% |
| 2021 | $590.48 Million | -69.99% |
| 2020 | $1.97 Billion | +58.06% |
| 2019 | $1.24 Billion | +2.82% |
| 2018 | $1.21 Billion | -42.88% |
| 2017 | $2.12 Billion | +71.98% |
| 2016 | $1.23 Billion | -45.38% |
| 2015 | $2.26 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Cellectis SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $106.17 Million USD |
| MoneyControl | $106.17 Million USD |
| MarketWatch | $106.17 Million USD |
| marketcap.company | $106.17 Million USD |
| Reuters | $106.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more